Pixantrone dimaleate for treating non-Hodgkin’s lymphoma

Bibliography

• Office for National Statistics. 2013. Available from: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html [Last accessed 2 January 2015]
   Google Scholar
• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Ann Rev Med 2008;59:239-50
   Web of Science ®Google Scholar
• Larouche JF, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010;28(12):2094-100
   PubMed Web of Science ®Google Scholar
• Gangatharan S, Kuruvilla J. Relapsed and refractory aggressive NHL: time for a change. Transfus Apher Sci 2013;49:72-9
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2012. Available from: http://www.esmo.org/Guidelines/Haematological-Malignancies [Last accessed 2 January 2015]
   Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Non-Hodgkin’s Lymphomas. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf [Last accessed 15 January 2015]
   Google Scholar
• Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev 2011;7(4):214-20
   PubMedGoogle Scholar
• Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-71
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159-65
   PubMed Web of Science ®Google Scholar
• Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of 3 trials. Cancer 2003;97:2869-79
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer. Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/faqs/#How [Last accessed 2 January 2015]
   Google Scholar
• Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28(21):3416-21
   PubMed Web of Science ®Google Scholar
• Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies. Cancer Manag Res 2013;5:251-69
   PubMedGoogle Scholar
• Evison BJ, Mansour OC, Menta E, et al. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 2007;35:3581-9
   PubMed Web of Science ®Google Scholar
• Evison BJ, Chiu F, Pezzoni G, et al. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008;74:184-94
   PubMed Web of Science ®Google Scholar
• Volpetti S, Zaja F, Fanin R. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther 2014;7:865–72
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Krapcho AP, Hacker MP. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: Aza-anthracenediones. Cancer Lett 1995;91:115-24
   PubMed Web of Science ®Google Scholar
• Evison BJ, Bilardi RA, Chiu F, et al. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucl Acids Res 2009;37(19):6355-70
   PubMed Web of Science ®Google Scholar
• Adnan N, Buck DP, Evison BJ, et al. DNA binding by pixantrone. Org Biomol Chem 2010;8:5359-66
   PubMed Web of Science ®Google Scholar
• Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013;344(2):467-78
   PubMed Web of Science ®Google Scholar
• Pean E, Flores B, Hudson I, et al. The european medicines agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013;18(5):625-33
   PubMed Web of Science ®Google Scholar
• Pixuvri 29. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf [Last accessed 2 January 2015]
   Google Scholar
• Cavalletti E, Crippa L, Mainardi P, et al. “Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone”. Invest New Drugs 2007;25(3):187-95
   PubMed Web of Science ®Google Scholar
• Dawson LK, Jodrell DI, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-9
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boige V, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7:43-50
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma. Ann Oncol 2001;12:661-7
   PubMed Web of Science ®Google Scholar
• Srokowski TP, Liebmann JE, Modiano MR, et al. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer 2011;117(22):5067-73
   PubMed Web of Science ®Google Scholar
• Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica 2003;88:888-94
   PubMed Web of Science ®Google Scholar
• Lim ST, Fayad L, Tulpule A, et al. A Phase I/II study of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2007;48(2):374-80
   PubMed Web of Science ®Google Scholar
• Borchmann P, Hebrecht R, Wilhelm M, et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisolone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2011;52(4):620-8
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Cernohous P, Engert A, et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol 2013;24:2618-23
   PubMed Web of Science ®Google Scholar
• Santoro A, Voglova J, Gabrail N, et al. Comparative trial of BBR 2778 (pixantrone) and rituximab versus single agent versus single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). J Clin Oncol(Meeting Abstracts) 2006;24(18_suppl):7578
   Web of Science ®Google Scholar
• Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase III, multicentre, open-label, randomised trial. Lancet Oncol 2012;13:696-706
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, Clinical trials. Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid=697997&version=HealthProfessional [Last accessed 15 January 2015]
   Google Scholar
• National Institute for Health and Care Excellence. Available from: https://www.nice.org.uk/guidance/ta306 [Last accessed 15 January 2015]
   Google Scholar
• Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005;129:597-606
   PubMed Web of Science ®Google Scholar
• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8(8):1039-58
   PubMed Web of Science ®Google Scholar